Insulin Packaging and the Environment: A Comprehensive Look at the Full Lifecycle

For the more than 530 million adults living with diabetes worldwide, insulin is not just a medication—it is a lifeline. Yet the very system that delivers this essential therapy generates a substantial environmental footprint that remains largely invisible to patients and providers alike. Every vial, every pre-filled syringe, every insulin pen passes through a complex chain of raw material extraction, manufacturing, distribution, use, and disposal. At each stage, it consumes resources, emits greenhouse gases, and produces waste. Understanding the full environmental impact of insulin packaging and disposal is essential for building a more sustainable diabetes care model—one that protects both human health and the planet.

This article examines the key packaging types for insulin, traces their environmental costs from cradle to grave, explores the challenges and risks of current disposal practices, and outlines actionable strategies for reducing harm. By shining a light on these often-overlooked aspects of diabetes care, we can begin to make informed choices that benefit both patients and the environment.

Insulin Packaging: Materials, Design, and Environmental Footprint

Insulin is available in several packaging formats, each with distinct environmental implications. The three most common types are glass vials, pre-filled syringes, and disposable insulin pens. A fourth format—reusable pen injectors with replaceable cartridges—is less common but offers a significantly lower waste profile. Understanding the material composition and manufacturing processes of each type is crucial for evaluating their sustainability.

Glass Vials

Glass vials are the oldest and most traditional packaging for insulin. They are typically made from type I borosilicate glass, which offers excellent chemical resistance and transparency, allowing patients to see the solution inside. The manufacturing process requires melting sand, soda ash, and limestone at extremely high temperatures (around 1500°C), a highly energy-intensive operation that emits approximately 0.7 to 1.0 kg of CO₂ per kilogram of glass produced. Additionally, the formation of vials involves blow-molding and annealing, which further adds to energy consumption.

While glass is theoretically infinitely recyclable without loss of quality, the reality is more complex. Insulin vials are small (typically 10 mL), and their narrow neck and small opening make them difficult to clean thoroughly. Residue of medication and labeling adhesives can contaminate the recycling stream. Many municipal recycling programs do not accept small glass containers, and even when they do, the vials often break during collection and are sorted out as cullet that is too small to be reprocessed. As a result, the vast majority of glass insulin vials end up in landfills or incinerators, where they persist for thousands of years or release emissions when burned.

Moreover, the production of glass vials is carbon-intensive. A 2021 life-cycle assessment published in the Journal of Cleaner Production found that glass containers for pharmaceuticals have a carbon footprint approximately 30% higher per unit volume than plastic alternatives, primarily due to the energy required for melting and forming. When transportation is factored in, the weight of glass further increases fuel consumption and associated emissions.

Pre-filled Syringes

Pre-filled syringes are single-use devices that combine the syringe barrel, plunger, needle, and insulin in one sealed unit. They are made primarily from medical-grade plastics such as polypropylene, polycarbonate, and cyclic olefin polymers. These materials offer durability, clarity, and compatibility with insulin, but they are derived from fossil fuels. The production of plastic syringes involves polymerization, molding, and assembly, all of which consume energy and release greenhouse gases.

According to a study by the University of Cambridge’s Department of Engineering, the carbon footprint of a single pre-filled plastic syringe is approximately 25–35 grams of CO₂ equivalent, compared to 40–50 grams for a single glass vial (including the rubber stopper and aluminum seal). However, the plastic syringe generates more solid waste by volume and is less likely to be recycled. The mixed polymers, combined with residual insulin and needle components, make mechanical recycling nearly impossible. Most pre-filled syringes are incinerated or landfilled. Incineration can recover energy but also releases CO₂ and potentially harmful emissions if the temperature or residence time is insufficient to destroy all organic compounds.

Disposable Insulin Pens

Disposable insulin pens are the most popular delivery device in many markets, valued for their convenience, portability, and dosing accuracy. They consist of an outer plastic barrel, a rubber plunger, a metal spring (in some models), a glass insulin cartridge (or a plastic prefilled reservoir), and a needle that is replaced for each injection. The pen body itself is designed for single-patient use but in practice is often discarded after the insulin is exhausted—typically after 28–30 days.

The environmental impact of disposable pens is substantial. A 2019 report by the International Diabetes Federation estimated that if all the estimated 500 million insulin pens used annually worldwide were placed end-to-end, they would stretch more than 75,000 kilometers. Most pens are made of multiple materials bonded together (plastic, metal, rubber, glass), making disassembly and recycling financially and technically unfeasible. Consequently, the vast majority are sent to landfill or incineration. A single disposable pen has a carbon footprint in the range of 60–100 grams CO₂ equivalent when considering materials, manufacturing, packaging, and transportation.

Furthermore, the needle component—typically in the range of 4–8 mm in length—is changed after each injection, generating up to 30 needles per cartridge use. Those needles, made of stainless steel and plastic, add their own waste stream. The World Health Organization estimates that approximately 16 billion injections are given each year globally, with diabetes accounting for a significant portion. Proper disposal of these sharps is a pressing environmental and public health issue.

Reusable Pens with Cartridges

Reusable insulin pens are designed to last for several years, with the patient replacing only the insulin cartridge when empty. These pens are usually made from more durable materials such as reinforced plastics or metal alloys. While the upfront manufacturing impact is higher than that of a disposable pen, the per-dose impact drops sharply over time. A life-cycle assessment by researchers at the University of Michigan found that a reusable pen used over two years produces 60% less plastic waste and 40% fewer greenhouse gas emissions compared to using disposable pens for the same period. If the pen is used for five years, the reduction in waste exceeds 80%.

However, reusable pens still require cartridges that are typically single-use glass or plastic containers with rubber septa. Those cartridges generate waste and need to be recycled or disposed of properly. Additionally, the pen body must be properly returned or recycled at end of life, which requires a circular system that is not yet widely implemented. Despite these limitations, reusable pens represent a clear environmental advantage over disposable alternatives.

The Full Lifecycle: From Raw Materials to End of Life

To fully appreciate the environmental burden of insulin packaging, one must look beyond the final disposal. The production lifecycle includes raw material extraction (mining for metals, drilling for oil for plastics, sand mining for glass), transportation of raw materials to factories, manufacturing and assembly, packaging in secondary containers (blister packs, cartons, leaflets), distribution to pharmacies and clinics, use by the patient, and finally disposal. Each stage consumes energy and water and generates pollution.

  • Raw material extraction: For glass, sand mining disrupts ecosystems and consumes water. For plastics, oil and gas drilling leads to spills, habitat destruction, and methane leakage. Metals for needles require mining that generates toxic tailings.
  • Manufacturing: High-temperature processes for glass and injection molding for plastics are energy-intensive. Chemical additives such as plasticizers, stabilizers, and dyes can introduce environmental pollutants.
  • Transportation: Insulin packaging is typically globally sourced. Glass vials are heavy and fragile, requiring sturdy secondary packaging that increases volume and weight. Refrigerated transport for insulin adds further energy demand.
  • Use: The device must remain sterile and functional. Patient education about proper disposal is critical but often lacking.
  • End of life: The mixed-material nature of most insulin devices makes recycling challenging. Incineration can recover energy but releases CO₂. Landfilling creates long-term persistence of plastics and potential leaching of additives.

Water Footprint

Water is consumed throughout the lifecycle. Glass manufacturing uses water for cooling and cleaning. Plastic production, especially for medical-grade polymers, requires large volumes of purified water. A comprehensive water footprint analysis for insulin packaging is not publicly available, but similar studies for pharmaceutical packaging suggest that a single pre-filled syringe may require 10–15 liters of water over its lifecycle, mostly in raw material processing and manufacturing.

Chemical Emissions

The production of plastic insulin devices involves the use of monomers, catalysts, and solvents that can be released into air and water if not properly controlled. Phthalates and bisphenol A (BPA) have historically been used in medical plastics, though many manufacturers have moved to alternatives. Still, the regulatory environment varies globally, and older materials may persist in some supply chains. Incineration of plastic devices at low temperatures can release dioxins and furans, which are persistent organic pollutants.

Disposal Challenges and Risks

The end-of-life stage of insulin packaging presents a host of environmental and public health challenges. Improper disposal is widespread, and the consequences range from pollution to injury.

Sharps Waste

The most immediate environmental and safety concern is the improper disposal of needles and lancets. Used sharps can pierce trash bags, injure waste workers, and create needle-stick injuries for community members. In the United States, the American Diabetes Association reports that millions of needles are disposed of in household trash each year, despite recommendations to use designated sharps containers. Even when placed in rigid containers, those containers often end up in landfills where they can break down over time, releasing sharp objects into the environment.

Sharps that are not properly contained can also enter waterways through sewage (when flushed, which is strongly discouraged) or through stormwater runoff if left in the open. This poses risks to wildlife and ecosystems. Aquatic animals can ingest or be entangled in plastic debris, while sharp edges can cause injury.

Plastic Accumulation and Microplastics

Disposable insulin pens and syringes are composed of plastics that can take hundreds of years to degrade in landfills. Over time, they break down into microplastics—particles smaller than 5 mm—that migrate into soil and water. Microplastics have been found in human blood, lungs, and placental tissue, raising concerns about potential health effects. The long-term consequences of microplastic exposure are not fully understood, but early research suggests links to inflammation, oxidative stress, and endocrine disruption.

Given that diabetes patients may use multiple disposable devices per day over a lifetime, the cumulative contribution to the microplastic burden is significant. A patient using two disposable pens per month for 30 years would generate approximately 720 pen bodies and 21,600 needles—a huge amount of non-biodegradable waste.

Chemicals in the Environment

Insulin itself is a protein hormone, and when discarded in landfills, it can break down naturally. However, if large quantities of unused insulin are disposed of incorrectly (e.g., flushed), they can contribute to pharmaceutical pollution in waterways. Even tiny concentrations of hormones can affect aquatic life—endocrine-disrupting effects have been documented in fish exposed to estrogen and other hormones. While insulin is less potent than some other pharmaceutical pollutants, the sheer volume of use and disposal makes it a concern.

Other chemical concerns include the rubber stoppers (which may contain accelerators and antioxidants), the aluminum seals on vials (which can leach into acidic environments), and the adhesives and inks used on labels and packaging.

Regulatory Landscape and Gaps

Regulations governing the disposal of insulin packaging vary widely by country. In many developed nations, used sharps must be placed in approved containers and collected through special waste programs. However, patient awareness and compliance remain low. In low- and middle-income countries, formal disposal systems are often absent or unaffordable, leading to widespread improper disposal.

The United Nations’ World Health Organization recommends safe management of healthcare waste, including segregation of sharps and pharmaceutical waste. But guidelines are rarely enforced for home-generated waste. Moreover, recycling of pharmaceutical packaging is seldom mandated or incentivized. In the European Union, the Waste Framework Directive encourages waste prevention and recycling, but medical devices are often exempted due to contamination concerns.

Strategies for Reducing Environmental Impact

Addressing the environmental footprint of insulin packaging requires coordinated action by manufacturers, healthcare providers, policymakers, and patients. The following strategies offer a roadmap for progress.

Design for Environment (DfE)

Manufacturers can reduce impacts by designing devices that use fewer materials, incorporate recycled content, and are easier to disassemble. For example, switching to single-material designs for pen bodies (all polypropylene) would improve recyclability. Eliminating metal springs in favor of plastic ones could also simplify processing. The use of biobased plastics from renewable feedstocks, such as polylactic acid (PLA), is an emerging area, though challenges remain with durability and sterilization.

Expanding Reusable Devices

Healthcare systems and payers can incentivize the use of reusable insulin pens and cartridges through coverage policies and patient education. The upfront cost of a reusable pen is higher, but the long-term savings in waste and carbon emissions are substantial. Some manufacturers already offer durable pen injectors that last for years. Increasing their market share would dramatically reduce per-dose waste.

Improving Recycling Infrastructure

Specialized recycling programs for medical devices are needed. In some countries, mail-back programs exist for insulin pens and sharps, where patients return used devices in prepaid containers for proper recycling or disposal. Scaling these programs with public funding or industry responsibility would increase participation. For glass vials, improved sorting technologies and dedicated collection streams could allow more effective recycling. The U.S. Environmental Protection Agency provides guidelines for sharps disposal, but adoption varies.

Take-Back and Extended Producer Responsibility (EPR)

Extended producer responsibility programs require manufacturers to finance the end-of-life management of their products. For insulin devices, an EPR scheme would mean that diabetes product makers contribute to a fund that supports collection, recycling, and safe disposal. Several European countries have applied EPR to products like batteries and electronics, but medical devices have largely been excluded. Advocacy by diabetes organizations could push for inclusion.

Patient Education and Point-of-Care Information

Most patients are not aware of the environmental impacts of their diabetes supplies. Healthcare providers can play a key role by discussing proper disposal during appointments and providing printed guides. Pharmacies can display clear signage and offer free sharps containers. Digital reminders and apps could also help. The American Diabetes Association and Diabetes UK both offer resources on waste reduction, but these need to be more prominently integrated into routine care.

Policy and Regulatory Reforms

Governments can require environmental impact assessments for new medical devices, set recycling targets, and ban the incineration of recyclable materials. Tax incentives could be offered for the use of recycled content or for the development of biodegradable alternatives. The WHO’s Global Waste Management Goals could be adapted to include home-generated healthcare waste.

Conclusion

The environmental impact of insulin packaging and disposal is a complex, multi-stakeholder issue that has been largely overlooked in the push for better diabetes outcomes. The carbon footprint, waste generation, and potential for pollution from glass vials, plastic syringes, and disposable pens are significant and growing as the global prevalence of diabetes rises. However, the path to sustainability is clear: designing for recyclability, promoting reusable devices, improving recycling infrastructure, implementing extended producer responsibility, and educating patients. Healthcare systems that integrate environmental sustainability into diabetes care will not only reduce their ecological footprint but also enhance patient safety and potentially lower costs over time. It is time for the diabetes community—patients, providers, manufacturers, and policymakers—to take responsibility for the full lifecycle of insulin delivery and work toward a future where safe, effective diabetes care does not come at the expense of the planet.